cancer research
cancer research
Learn about what cancer research and treatment options might look like in 2050.
AbbVie (A Britannica Publishing Partner)
Transcript
TOM HUDSON: In 2050, cancer, the diagnosis and treatment of cancer will be very different. They're obviously be a lot of new drugs, which are going to target specific things in tumors, but we also want to look always want to look at the tumor in every patient. I come from the genome world.
I was part of the Human Genome Project, mapping genes and chromosomes. And that became the Genome Project. It took us a decade to sequence that first genome. Now, we're doing it regularly in a lab to do in a week or in a couple of days.
I think in 2050, it's going to be done routinely. When you have someone that has a tumor that's detected in the blood, you'll sequence its genome. If the tumor comes back, you're going to sequence its genome every time to see what's changed so you can target it specifically.
SCOTT DYLLA: I see treatment options being very different in 2050 is hopefully we have a spectrum of different therapies that are all highly effective, but we can pick the one off the shelf that works best in any particular patient based on how we understand their tumor based on what their tumor looks like and what the DNA mutations present are.
I was part of the Human Genome Project, mapping genes and chromosomes. And that became the Genome Project. It took us a decade to sequence that first genome. Now, we're doing it regularly in a lab to do in a week or in a couple of days.
I think in 2050, it's going to be done routinely. When you have someone that has a tumor that's detected in the blood, you'll sequence its genome. If the tumor comes back, you're going to sequence its genome every time to see what's changed so you can target it specifically.
SCOTT DYLLA: I see treatment options being very different in 2050 is hopefully we have a spectrum of different therapies that are all highly effective, but we can pick the one off the shelf that works best in any particular patient based on how we understand their tumor based on what their tumor looks like and what the DNA mutations present are.